Therapeutic potential of splice-switching oligonucleotides. - Wikidata - wikimedia - TriplyDB

Therapeutic potential of splice-switching oligonucleotides.

Therapeutic potential of splice-switching oligonucleotides.

http://www.wikidata.org/entity/Q37363171

about

A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophy B Cell Receptor Activation Predominantly Regulates AKT-mTORC1/2 Substrates Functionally Related to RNA Processing Synthetic oligonucleotides recruit ILF2/3 to RNA transcripts to modulate splicing Silencing disease genes in the laboratory and the clinic Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers.Enhancement of β-Globin Gene Expression in Thalassemic IVS2-654 Induced Pluripotent Stem Cell-Derived Erythroid Cells by Modified U7 snRNA.An antisense microwalk reveals critical role of an intronic position linked to a unique long-distance interaction in pre-mRNA splicing Improved Performance of Anti-miRNA Oligonucleotides Using a Novel Non-Nucleotide Modifier.Anti-tumor activity of splice-switching oligonucleotides.Flavin conjugates for delivery of peptide nucleic acids.Efficient in vivo manipulation of alternative pre-mRNA splicing events using antisense morpholinos in mice.Human slow troponin T (TNNT1) pre-mRNA alternative splicing is an indicator of skeletal muscle response to resistance exercise in older adults.Antitumorigenic potential of STAT3 alternative splicing modulation Expanding the action of duplex RNAs into the nucleus: redirecting alternative splicing.Argonaute and the nuclear RNAs: new pathways for RNA-mediated control of gene expression.Polymer nanoparticle-mediated delivery of microRNA inhibition and alternative splicing Tuning of alternative splicing--switch from proto-oncogene to tumor suppressor U1 Adaptor Oligonucleotides Targeting BCL2 and GRM1 Suppress Growth of Human Melanoma Xenografts In Vivo Enhanced splice correction by 3', 5'-serinol and 2'-(ω-O-methylserinol) guarded OMe-RNA/DNA mixmers in cells Emerging role of alternative splicing of CRF1 receptor in CRF signaling.Molecular therapy in myotonic dystrophy: focus on RNA gain-of-function.Perspectives on gene therapy in myotonic dystrophy type 1.Cellular delivery of siRNA and antisense oligonucleotides via receptor-mediated endocytosis.Oligonucleotide conjugates for therapeutic applications.Type 1 diabetes in mice and men: gene expression profiling to investigate disease pathogenesis.Self-antigen expression in the peripheral immune system: roles in self-tolerance and type 1 diabetes pathogenesis.Transcription factor decoy: a pre-transcriptional approach for gene downregulation purpose in cancer.Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells.Abnormalities in Alternative Splicing of Apoptotic Genes and Cardiovascular Diseases.Alternative splicing: the pledge, the turn, and the prestige : The key role of alternative splicing in human biological systems.A high-throughput screening assay for the functional delivery of splice-switching oligonucleotides in human melanoma cells.Direct oligonucleotide-photosensitizer conjugates for photochemical delivery of antisense oligonucleotides.Nuclease resistant oligonucleotides with cell penetrating properties.Transposon-mediated Generation of Cellular and Mouse Models of Splicing Mutations to Assess the Efficacy of snRNA-based Therapeutics Modulation of RNA splicing as a potential treatment for cancer.Magnetic Nanoparticle Assisted Self-assembly of Cell Penetrating Peptides-Oligonucleotides Complexes for Gene Delivery.Dendrimer Conjugates for Light-activated Delivery of Antisense Oligonucleotides.Antisense Oligonucleotides Modulating Activation of a Nonsense-Mediated RNA Decay Switch Exon in the ATM Gene.Novel viral vectors utilizing intron splice-switching to activate genome rescue, expression and replication in targeted cells.PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation.

P2860

Q28244480-8BF5ED16-53E4-44E2-A47B-BAE883339BB4 Q28553375-EC25DC61-090C-4138-A8EE-75F5FA34F650 Q28830393-F5010B93-FB65-4A7D-A97D-C38E9EF0589B Q29039090-198B965A-EE1E-4C36-8AA5-A6BF8893176C Q33573648-421DFE93-3D5C-4EDF-B630-4E100C2AAAEC Q33722582-5ECEA076-CFF6-427C-9070-F0E733C3F6AB Q33867447-E46892C0-6FD8-4504-A009-7E7E44EECB87 Q34367048-0258BA92-CCD1-4CA6-A16F-22883643A60A Q34401490-72E67AB7-F1D9-4C26-A031-E683F17720A6 Q34468029-ACD49995-9DFB-4C49-93EC-0D3C3FAE003E Q34675818-966489FF-EF64-4370-A9CF-D85D74B27631 Q34974513-EE1E3E88-59A9-4745-8E19-5EF97CCCCD72 Q35471200-5482D3E4-A035-4E54-9E8F-AE1052D96303 Q35740521-E1ECA683-F5B7-4261-861F-0118744A6215 Q35867143-76E923A4-3B71-4546-9CE4-027C9505AA48 Q36004826-7E2A3A63-B092-4608-8B9D-CB71FD84A0D2 Q36503982-678AB2CB-FA43-4D33-81E6-4E6431E66B97 Q36757152-984CDA8F-7BE9-4ABD-A8E5-89A5D3886845 Q37655781-DF4DEA65-F99F-4712-90AE-9C2745929DFF Q37710423-43F9C604-BB2D-4DB7-938F-10D4ACFECC8B Q37734660-3622F17F-76DF-4119-A64C-341EE71AB3FF Q37831858-C6E51698-E061-471F-8ED1-2C10762FF207 Q37850458-37545FF9-841F-47B3-87AF-4255B485EF92 Q38123854-8EDA1596-3E52-4D73-A17B-8D41534A39E3 Q38200560-A9B30B91-F0CD-441A-B1EC-0438A6F76077 Q38230215-710D0E8A-B500-4850-B7B6-FDFE5D259D30 Q38300047-927598DE-B1D9-4777-BC4E-A5CDEE5B945C Q38324414-04639442-D2F6-4274-9E36-ADF33E8F5A5D Q38637311-A07A8F93-BB9A-41EA-981D-65287B39590C Q38735423-8BD335C0-BA07-48F7-BADE-7BF23EBC1360 Q38884283-7FE0B21E-4379-4858-8E7B-0174D79F9549 Q38898015-F9E4ED57-7943-4942-B1AC-56C6533AFF8C Q38911554-5121685C-DCF8-4323-8697-FC68230F2263 Q39145734-742B9263-45C8-4B84-BBC7-A899348EDC01 Q39427653-C5F7B13D-AD4B-4C36-A2C3-63788A81293A Q41490579-D93F3DCF-19E4-4418-8B89-725C97589027 Q41573307-159290A6-99FA-4430-8DAA-E5F7880A7334 Q42177295-6BE4A04C-57B6-42F8-96C4-5CABF047ABCF Q42189992-B047A198-BD10-4D8A-B215-C7E4D33481B7 Q42787946-BFD575BC-A7DD-420F-8089-DCE2C1AF0D6C

P2860

Therapeutic potential of splice-switching oligonucleotides.

http://www.wikidata.org/entity/Q37363171

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Therapeutic potential of splice-switching oligonucleotides.

@en

Therapeutic potential of splice-switching oligonucleotides.

@nl

type

label

Therapeutic potential of splice-switching oligonucleotides.

@en

Therapeutic potential of splice-switching oligonucleotides.

@nl

prefLabel

Therapeutic potential of splice-switching oligonucleotides.

@en

Therapeutic potential of splice-switching oligonucleotides.

@nl

P1433

Q37363171-9D47F68A-22F2-4D22-90DE-97882ADB4916

P1476

Q37363171-ADD954FB-917F-42D2-9B35-54779B5C55F1

P2093

Q37363171-9CC992F6-F550-4F26-8C2F-F070E12230E5

Q37363171-CE2C3852-1F62-41D8-B380-29302441F2CE

P2860

Q37363171-00F09D8F-E3AA-418E-8FA9-AE72D08EDE81

Q37363171-05534CD2-134F-4925-8E85-E4E631A8E7CA

Q37363171-058C05D8-3171-4A74-AB98-87CAF5ED1300

Q37363171-0768EDEB-8588-4053-B8EF-68E91E986617

Q37363171-0A14DF1F-708E-4511-8EAA-51F223C991B0

Q37363171-0CC66E0E-17F3-4F84-ADB1-6974218B1737

Q37363171-0DDC4FF4-1070-4AAE-890C-0F987CB9FC27

Q37363171-1104B6ED-23B9-4DA8-91A2-C83AF1809259

Q37363171-11471FEA-A5A4-4B8D-9FAB-23F5D917FBAC

Q37363171-1A652B11-0E50-4E1A-B181-8BF9AF1A102C

P304

Q37363171-0EB82ACC-CE2D-4FDF-BD3B-20529429A315

P31

Q37363171-5AAB9D7B-5F8D-4F53-94E2-72642D0A8B88

P356

Q37363171-013B040E-C496-4713-8B62-EFBAA493B9E2

P433

Q37363171-A7514D80-5A72-41FD-9A3F-2282227ADC1A

P478

Q37363171-7C53A0B8-6B76-4682-9820-DCF3102F1B0E

P50

Q37363171-AE1E89F2-7A12-4DD6-BB29-E4F2F472A9EF

P577

Q37363171-1D06AC6A-FEAF-443C-A582-A7111EA13911

P5875

Q37363171-6D70A5B4-3D39-4789-AF75-A12585B54924

P698

Q37363171-D9810B7C-AEE8-4C57-B92E-A6F0E14B6632

P932

Q37363171-66695D57-B17B-47C0-8D2F-30F575B1523E

P356

P1433

Oligonucleotides

P1476

Therapeutic potential of splice-switching oligonucleotides.

@en

P2093

John Bauman

http://www.w3.org/2001/XMLSchema#string

Natee Jearawiriyapaisarn

http://www.w3.org/2001/XMLSchema#string

P2860

Drug treatment for myotonia

Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs

Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides

Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients

Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy

Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity

The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor

Regulation of interleukin-1- and lipopolysaccharide-induced NF-kappaB activation by alternative splicing of MyD88

Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays

Understanding alternative splicing: towards a cellular code

P304

1-13

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/OLI.2008.0161

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23760653

http://www.w3.org/2001/XMLSchema#string

P698

19125639

http://www.w3.org/2001/XMLSchema#string

P932

2663420

http://www.w3.org/2001/XMLSchema#string